Innovent Biologics sees share capital rise from option exercises

Innovent Biologics, Inc. reported an increase of 775,154 ordinary shares in its issued share capital for the month ended 30 September 2025, bringing the total to 1,713,520,033 issued shares. This change primarily resulted from the exercise of share options under its share incentive plans.

The company's Pre-IPO Share Incentive Plan saw 564,500 new shares issued upon exercise, reducing outstanding options from 9,428,094 to 8,863,594. Additionally, 210,654 shares were issued from the Post-IPO share option scheme, with 45,859,211 options remaining. The 2024 Share Scheme had 3,982,135 options outstanding after 49,000 were cancelled. Total funds raised from the exercise of options during the month amounted to HK$13,097,191.45.

The total authorized/registered share capital remained stable at 5,000,000,000 ordinary shares with a par value of $0.00001, totaling $50,000. There were no movements in treasury shares during the reporting period.